secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunome Inc. (IMNM)
CIK:        0001472012
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001104659-24-117682
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunome Q3 net loss $47.1M, cash $240.1M; AL102 topline data H2 2025
---------------------------------------------------------------------

- Net loss of $47.1M for Q3 2024; cash, equivalents and marketable securities $240.1M as of Sept 30, 2024.
- R&D expenses $37.2M; in-process R&D $6.7M (related to business development); G&A $9.5M.
- Phase 3 RINGSIDE Part B for AL102 fully enrolled; topline data expected H2 2025.
- IND submissions for IM-1021 and IM-3050 on track for Q1 2025.
- Cash runway expected to extend into 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472012/000110465924117682/0001104659-24-117682-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472012/000110465924117682/tm2428220d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-117682

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer